Development and Update of Guideline-based Quality Indicators in Lung Cancer.

Autor:	Utzig M; Zertifizierung, Deutsche Krebsgesellschaft e.V., Berlin, Germany., Hoffmann H; Division of Thoraxchirurgie, Klinikum rechts der Isar der Technischen Universität München, München, Germany., Reinmuth N; Thorakale Onkologie, Asklepios Fachkliniken München-Gauting, Gauting, Germany., Schütte W; Klinik für Innere Medizin II, Krankenhaus Martha-Maria Halle-Dölau gGmbH, Halle, Germany., Langer T; Leitlinienprogramm Onkologie, Deutsche Krebsgesellschaft e.V., Berlin, Germany., Lobitz J; Wissensmanagement/Infonetz Krebs, Deutsche Krebsgesellschaft e.V., Berlin, Germany., Rückher J; Zertifizierung, Deutsche Krebsgesellschaft e.V., Berlin, Germany., Wesselmann S; Zertifizierung, Deutsche Krebsgesellschaft e.V., Berlin, Germany.
Jazyk:	angličtina
Zdroj:	Pneumologie (Stuttgart, Germany) [Pneumologie] 2024 Apr; Vol. 78 (4), pp. 250-261. Date of Electronic Publication: 2023 Dec 11.
DOI:	10.1055/a-2204-4879
Abstrakt:	Background: In 2022, an update of the German lung cancer guideline, first published in 2010 and revised in 2018, was released. This article aims to show the process of updating, developing, and implementing guideline-based quality indicators (QI) into the certification system for lung cancer centers (LCC). Methods: A multidisciplinary and interprofessional working group revised the guideline QIs from 2018 using the strong recommendations of the guideline update, a systematic review for QIs, and the results of the implemented QIs from LCC. Results: For 4 out of 8 indicators from the 2018 guideline, the LCC showed an improved implementation of the requirements in the last 3 years (2018-2020). For 3 indicators, the median of the results was constant at a very high level (≥96% or 100%). Only the "adjuvant cisplatin-based chemotherapy" indicator showed declining values between 2018 and 2020. The target values and plausibility limits were well achieved by LCC. After updating the guideline, one QI from 2018 was not included in the new QI set due to the small denominator population. Based on the new strong recommendations, 8 new QIs were defined. From the QI set of the guideline update, 13 of 15 indicators (7 since 2018 and 6 from 2022 on) were adopted into the certification program. Conclusions: The guideline recommendations are implemented by LCC at a high level. The process presented confirms the successful implementation of the so-called quality cycle in oncology. The QIs developed by the German Guideline Program in Oncology (GGPO) are adopted by the certification program. The implementation of the QI is measured in LCC, evaluated by the German Cancer Society (DKG), and reflected back to the GGPO. The "real world" data have led to the deletion of one QI and show a high implementation of most QIs in LCC. Competing Interests: Martin Utzig, Thomas Langer, Jessica Lobitz, Johannes Rückher, and Simone Wesselmann are employees of the German Cancer Society (Deutsche Krebsgesellschaft e.V.). Hans Hoffmann is the representative of the German Society for Thoracic Surgery (DGT) in the Certification Commission for Lung Cancer Centers and a member of the Guideline Commission S3 Guideline Lung Cancer. Niels Reinmuth is the representative of the German Respiratory Society (DGP) in the Certification Commission for Lung Cancer Centers and a member of the Guideline Commission S3 Guideline Lung Cancer. Wolfgang Schütte is the Guideline Commission S3 Guideline Lung Cancer coordinator and represents it in the Certification Commission for Lung Cancer Centers. (Thieme. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu